Protalix BioTherapeutics (FRA:PBDA) Total Long-Term Assets : €13.27 Mil (As of Mar. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Total Long-Term Assets?

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Protalix BioTherapeutics's Total Long-Term Assets for the quarter that ended in Mar. 2024 was €13.27 Mil.

Protalix BioTherapeutics Total Long-Term Assets Historical Data

The historical data trend for Protalix BioTherapeutics's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Total Long-Term Assets Chart

Protalix BioTherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Long-Term Assets

Get a 7-Day Free Trial

11.62

10.04

10.62

10.30

13.30

Protalix BioTherapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Long-Term Assets	Get a 7-Day Free Trial															10.42	13.70	14.01	13.30	13.27

Protalix BioTherapeutics Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Protalix BioTherapeutics Total Long-Term Assets Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Total Long-Term Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Protalix BioTherapeutics (FRA:PBDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Total Long-Term Assets

Comparable Companies

Traded in Other Exchanges

PLX:USA

Address

2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601

Website

https://www.protalix.com

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.

Protalix BioTherapeutics (FRA:PBDA) Headlines

No Headlines